Aastrom Biosciences, Inc. (Aastrom) is a development-stage company. The Company is a regenerative medicine company focused on the development of cell therapies to repair or regenerate damaged or diseased tissues. The Company is developing patient-specific, expanded multicellular therapies for use in the treatment of severe, chronic ischemic cardiovascular diseases. The Company�s cell-manufacturing technology enables the manufacture of multicellular therapies, expanded from an adult patient�s own bone marrow, to be delivered directly to damage tissues. In March 2013, it announced strategic change in research and development programs to focus on the clinical development of lead product, ixmyelocel-T, for the treatment of dilated cardiomyopathy (DCM). In June 2014, the Company acquired Sanofi's cell therapy and regenerative medicine (CTRM) business unit.